NZ522953A - Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate - Google Patents
Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearateInfo
- Publication number
- NZ522953A NZ522953A NZ522953A NZ52295301A NZ522953A NZ 522953 A NZ522953 A NZ 522953A NZ 522953 A NZ522953 A NZ 522953A NZ 52295301 A NZ52295301 A NZ 52295301A NZ 522953 A NZ522953 A NZ 522953A
- Authority
- NZ
- New Zealand
- Prior art keywords
- valsartan
- tablet
- colloidal
- magnesium stearate
- silicon dioxide
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims abstract description 45
- 229960004699 valsartan Drugs 0.000 title claims abstract description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 title claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 title claims abstract description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 title claims abstract description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 title claims abstract description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 229960000913 crospovidone Drugs 0.000 title claims abstract description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 title claims abstract description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 title claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 title claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 title claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 title claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims abstract 3
- 238000005469 granulation Methods 0.000 claims abstract description 3
- 230000003179 granulation Effects 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 description 37
- 239000003826 tablet Substances 0.000 description 37
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 32
- 239000013543 active substance Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 21
- 239000006186 oral dosage form Substances 0.000 description 20
- 239000000654 additive Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 150000003839 salts Chemical group 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000005056 compaction Methods 0.000 description 9
- 239000007884 disintegrant Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920003084 Avicel® PH-102 Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 238000009490 roller compaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001463143 Auca Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940074619 diovan Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ540748A NZ540748A (en) | 2000-06-22 | 2001-06-20 | An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59968700A | 2000-06-22 | 2000-06-22 | |
| PCT/EP2001/006983 WO2001097805A2 (en) | 2000-06-22 | 2001-06-20 | Solid valsartan pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ522953A true NZ522953A (en) | 2005-10-28 |
Family
ID=24400655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ522953A NZ522953A (en) | 2000-06-22 | 2001-06-20 | Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate |
| NZ540748A NZ540748A (en) | 2000-06-22 | 2001-06-20 | An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ540748A NZ540748A (en) | 2000-06-22 | 2001-06-20 | An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1 |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2072049A3 (enExample) |
| JP (3) | JP2003535895A (enExample) |
| KR (2) | KR100659644B1 (enExample) |
| CN (2) | CN100450478C (enExample) |
| AU (2) | AU2001285768B2 (enExample) |
| BR (1) | BR0111868A (enExample) |
| CA (1) | CA2411882C (enExample) |
| CZ (1) | CZ20024180A3 (enExample) |
| EC (1) | ECSP024389A (enExample) |
| HK (1) | HK1052868A1 (enExample) |
| HU (1) | HUP0301390A3 (enExample) |
| IL (2) | IL153428A0 (enExample) |
| MX (1) | MXPA02012683A (enExample) |
| NO (1) | NO20026123L (enExample) |
| NZ (2) | NZ522953A (enExample) |
| PL (1) | PL358290A1 (enExample) |
| RU (1) | RU2333757C2 (enExample) |
| SG (1) | SG162605A1 (enExample) |
| SK (1) | SK18062002A3 (enExample) |
| WO (1) | WO2001097805A2 (enExample) |
| ZA (1) | ZA200210359B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2281978T3 (es) * | 1998-12-23 | 2007-10-01 | Novartis Ag | Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2. |
| EP1467728B1 (en) * | 2002-01-17 | 2007-08-22 | Novartis AG | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
| KR20080083071A (ko) * | 2003-08-08 | 2008-09-12 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| AU2005318365B2 (en) | 2004-12-24 | 2011-02-03 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| JP2009001520A (ja) * | 2007-06-21 | 2009-01-08 | Kowa Co | ジフェンヒドラミン含有固形製剤 |
| RU2487710C2 (ru) | 2007-10-09 | 2013-07-20 | Новартис Аг | Фармацевтическая композиция валсартана |
| WO2009059605A1 (en) * | 2007-11-08 | 2009-05-14 | University Of Copenhagen | Small scale solid state screening |
| EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
| WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| CN102362865B (zh) * | 2011-10-28 | 2013-06-26 | 山东司邦得制药有限公司 | 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用 |
| WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
| CN103599084B (zh) * | 2013-11-22 | 2018-10-30 | 威海迪素制药有限公司 | 一种降压组合物 |
| CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
| CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000024I1 (de) | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| FI963611A0 (fi) | 1994-03-17 | 1996-09-13 | Ciba Geigy Ag | Diabeettisen munuaissairauden hoito valsartaanilla |
| ATE209047T1 (de) * | 1995-06-07 | 2001-12-15 | Searle & Co | Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen |
| JPH11513395A (ja) * | 1995-10-06 | 1999-11-16 | ノバルティス・アクチエンゲゼルシャフト | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト |
| US6174910B1 (en) * | 1996-02-29 | 2001-01-16 | Novartis Ag | AT1 receptor antagonist for the stimulation of apoptosis |
| DE69726729T2 (de) * | 1996-05-20 | 2004-12-02 | Janssen Pharmaceutica N.V. | Fungizide mittel mit verbesserter bioverfügbarkeit |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| ES2281978T3 (es) * | 1998-12-23 | 2007-10-01 | Novartis Ag | Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2. |
| AR032152A1 (es) * | 2000-04-12 | 2003-10-29 | Novartis Ag | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica |
-
2001
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active Expired - Fee Related
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 CA CA2411882A patent/CA2411882C/en not_active Expired - Fee Related
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 HK HK03104842.9A patent/HK1052868A1/zh unknown
- 2001-06-20 EP EP09004205A patent/EP2072049A3/en not_active Withdrawn
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active Expired - Fee Related
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/en not_active Ceased
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 EP EP01965014A patent/EP1296677A2/en not_active Ceased
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
-
2002
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
-
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
-
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6858228B2 (en) | Solid oral dosage forms of valsartan | |
| CA2411882C (en) | Solid valsartan pharmaceutical compositions | |
| US20100267789A1 (en) | Tablet formulations comprising valsartan | |
| AU2001285768A1 (en) | Solid valsartan pharmaceutical compositions | |
| AU2005200815B2 (en) | Solid valsartan pharmaceutical compositions | |
| HK1083452B (zh) | 药物组合物 | |
| HK1019858B (en) | Process for forming solid oral dosage forms of valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |